PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24033947-13	2013	The ERK1/2 inhibitor PD98059 attenuated the IHinduced AT1R increase but the p38MAPK inhibitor SB203580 did not.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	21-28	angiotensin II receptor, type 1a	Rattus norvegicus	54-58	
23500546-5	2013	It was found that mRNA, protein, and current density of K(Ca)3.1 channels were greatly enhanced in cultured cardiac fibroblasts treated with 1 muM Ang II, and the effects were countered by the angiotensin type 1 receptor (AT1R) blocker losartan, the p38-MAPK inhibitor SB203580, the ERK1/2 inhibitor PD98059, and the PI3K/Akt inhibitor LY294002.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	300-307	angiotensin II receptor, type 1a	Rattus norvegicus	193-220	
23500546-5	2013	It was found that mRNA, protein, and current density of K(Ca)3.1 channels were greatly enhanced in cultured cardiac fibroblasts treated with 1 muM Ang II, and the effects were countered by the angiotensin type 1 receptor (AT1R) blocker losartan, the p38-MAPK inhibitor SB203580, the ERK1/2 inhibitor PD98059, and the PI3K/Akt inhibitor LY294002.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	300-307	angiotensin II receptor, type 1a	Rattus norvegicus	222-226	
20927110-7	2010	AngII-induced ERK 1/2 phosphorylation and cell proliferation in SHR were inhibited by pretreatment with an AT1 receptor blocker, candesartan and an inhibitor of MEK, PD98059.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	166-173	angiotensin II receptor, type 1a	Rattus norvegicus	107-110	
22180636-10	2012	Subsequent studies using MEK inhibitor PD98059 prevented 13cRA-mediated AT1 down-regulation and restored AngII-mediated intracellular calcium response.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	39-46	angiotensin II receptor, type 1a	Rattus norvegicus	72-75	
22366193-8	2012	Pretreatment of cells with the MEK inhibitor PD98059 prevented 2ME2-induced ERK1/2 phosphorylation and down-regulation of AT1R expression, which suggests that the observed inhibitory effect is mediated through ERK1/2 signaling intermediates.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	45-52	angiotensin II receptor, type 1a	Rattus norvegicus	122-126	
22322600-8	2012	Pretreatment of the cells with a MAPK kinase (MEK)-specific inhibitor PD98059 prevented TA-induced MAPK phosphorylation and down-regulation of the AT1R.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	70-77	angiotensin II receptor, type 1a	Rattus norvegicus	147-151	
11230331-7	2001	The Ang II-induced AT(1)-R mRNA downregulation was also blocked by PD98059, an extracellular signal-regulated protein kinase (ERK) kinase inhibitor.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	67-74	angiotensin II receptor, type 1a	Rattus norvegicus	19-26	
19286949-7	2009	ANG II-induced AT(1)R expression was blocked by ICV infusion of the p44/42 MAPK inhibitor PD-98059 (0.025 microg/h) and the JNK inhibitor SP-600125 (0.125 microg/h), but not by the p38 MAPK inhibitor SB-203580 (0.125 microg/h).	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	90-98	angiotensin II receptor, type 1a	Rattus norvegicus	15-21	
18768402-7	2008	A 4-week ICV infusion of the p44/42 MAPK inhibitor PD98059 or the c-Jun N-terminal kinase inhibitor SP600125 significantly decreased AT(1)-R protein and AT(1)-R immunoreactivity in the paraventricular nucleus and subfornical organ, but the p38 MAPK inhibitor SB203580 did not.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	51-58	angiotensin II receptor, type 1a	Rattus norvegicus	133-140	
18768402-7	2008	A 4-week ICV infusion of the p44/42 MAPK inhibitor PD98059 or the c-Jun N-terminal kinase inhibitor SP600125 significantly decreased AT(1)-R protein and AT(1)-R immunoreactivity in the paraventricular nucleus and subfornical organ, but the p38 MAPK inhibitor SB203580 did not.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	51-58	angiotensin II receptor, type 1a	Rattus norvegicus	153-160	
18768402-9	2008	In untreated HF rats 4 weeks after coronary ligation, a 3-hour ICV infusion of PD98059, SP600125, or losartan reduced AT(1)-R mRNA in paraventricular nucleus and subfornical organ.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	79-86	angiotensin II receptor, type 1a	Rattus norvegicus	118-125	
9314416-8	1997	MAP kinase was involved in this phosphorylation, a conclusion supported by the following evidence: (1) exogenous MAP kinase phosphorylated the AT1 receptor; (2) PD98059, a MAP kinase kinase inhibitor, attenuated Ang II-stimulated AT1 receptor phosphorylation; and (3) MAP kinase and AT1 receptors were coimmunoprecipitated in Ang II-stimulated neurons.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	161-168	angiotensin II receptor, type 1a	Rattus norvegicus	143-146	
9314416-8	1997	MAP kinase was involved in this phosphorylation, a conclusion supported by the following evidence: (1) exogenous MAP kinase phosphorylated the AT1 receptor; (2) PD98059, a MAP kinase kinase inhibitor, attenuated Ang II-stimulated AT1 receptor phosphorylation; and (3) MAP kinase and AT1 receptors were coimmunoprecipitated in Ang II-stimulated neurons.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	161-168	angiotensin II receptor, type 1a	Rattus norvegicus	230-233	
9314416-8	1997	MAP kinase was involved in this phosphorylation, a conclusion supported by the following evidence: (1) exogenous MAP kinase phosphorylated the AT1 receptor; (2) PD98059, a MAP kinase kinase inhibitor, attenuated Ang II-stimulated AT1 receptor phosphorylation; and (3) MAP kinase and AT1 receptors were coimmunoprecipitated in Ang II-stimulated neurons.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	161-168	angiotensin II receptor, type 1a	Rattus norvegicus	230-233